| Literature DB >> 31959954 |
Jessica Perrin1, Thilo Werner1, Nils Kurzawa2, Anna Rutkowska1, Dorothee D Childs2, Mathias Kalxdorf1, Daniel Poeckel1, Eugenia Stonehouse1, Katrin Strohmer1, Bianca Heller1, Douglas W Thomson1, Jana Krause1, Isabelle Becher2, H Christian Eberl1, Johanna Vappiani1, Daniel C Sevin1, Christina E Rau1, Holger Franken1, Wolfgang Huber2, Maria Faelth-Savitski1, Mikhail M Savitski3, Marcus Bantscheff4, Giovanna Bergamini5.
Abstract
Monitoring drug-target interactions with methods such as the cellular thermal-shift assay (CETSA) is well established for simple cell systems but remains challenging in vivo. Here we introduce tissue thermal proteome profiling (tissue-TPP), which measures binding of small-molecule drugs to proteins in tissue samples from drug-treated animals by detecting changes in protein thermal stability using quantitative mass spectrometry. We report organ-specific, proteome-wide thermal stability maps and derive target profiles of the non-covalent histone deacetylase inhibitor panobinostat in rat liver, lung, kidney and spleen and of the B-Raf inhibitor vemurafenib in mouse testis. In addition, we devised blood-CETSA and blood-TPP and applied it to measure target and off-target engagement of panobinostat and the BET family inhibitor JQ1 directly in whole blood. Blood-TPP analysis of panobinostat confirmed its binding to known targets and also revealed thermal stabilization of the zinc-finger transcription factor ZNF512. These methods will help to elucidate the mechanisms of drug action in vivo.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31959954 DOI: 10.1038/s41587-019-0388-4
Source DB: PubMed Journal: Nat Biotechnol ISSN: 1087-0156 Impact factor: 54.908